A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether the study drug, enfortumab vedotin, is an
effective and safe treatment for people who have urothelial carcinoma of the upper urinary
tract. Study participants will be people who are not eligible to receive or have chosen not
to receive the chemotherapy drug cisplatin for treatment of their cancer. In addition, all
participants will be planning on having standard surgery to remove their tumor.